{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-274908","form_type":"8-K","ticker":"BMEA","cik":"0001840439","company_name":"Biomea Fusion, Inc.","filed_at":"2022-11-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.631454+00:00","generated_at":"2026-06-22T19:16:44.871227+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Biomea Fusion doses first T2D patient in Phase II of BMF-219; Phase I completed","bullets":["First patient with type 2 diabetes dosed in Phase II portion of COVALENT-111 (Phase I/II) of BMF-219.","Phase I healthy volunteer portion completed; BMF-219 well tolerated with favorable PK/PD profile.","BMF-219 is the first menin inhibitor to reach clinic for type 2 diabetes; aims to restore beta cells.","Initial Phase II data expected in first half of 2023; IND filing with FDA on track for Q4 2022.","Preclinical data showed BMF-219 ability to restore beta cell mass in animal models of T2D."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-274908","json":"https://secwatch.observer/filing/0001193125-22-274908.json","markdown":"https://secwatch.observer/filing/0001193125-22-274908.md","text":"https://secwatch.observer/filing/0001193125-22-274908.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840439/000119312522274908/0001193125-22-274908-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840439/000119312522274908/d350423d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T19:16:44.871227+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}